**IL-10 in triple negative metastatic Breast Cancer**

**Introduction**: IL-10 is an anti-inflammatory cytokine and with other cytokines and chemokines, influence the innate and adaptive immune responses by T cell activity and anti-inflammatory macrophages. Cancer cells are highly adaptive and escape immune control. One of important mechanisms of secretion anti-inflammatory cytokines into the TME. Many studies have reported the increased expression of IL-10 in Breast cancer. IL-10 inhibiting T-cell proliferation. Breast cancer is the most common cancer among women and triple negative breast cancer is one of the progressive and challenging one. IL-10 is secreted by tumor cells. The level of expression was more in tumor and breast cancer cell co-culture environment. changing this immune response is mor important in new immunotherapy treatments.

**Methods**: we checked IL-10 with immunohistochemistry between 30 metastatic and non-metastatic triple negative breast cancer and IL-10 level in serum.

**Results**: 23 metastatic breast cancer samples exhibited a strong expression of IL-10 and IL-10 was associated with higher metastatic rate. the serum IL-10 was similar, and no significant difference observed.

**Conclusion**: IL-10 in is one of the factors which may have role in immunotherapy planning in triple-negative breast cancer. in triple negative breast cancer IL-10 is a negative predictor factor and has higher level in metastatic Breast Cancer. IL-10 serum level may not be good marker for prognosis.